Clinical trials: Depressive Disorder, Treatment-Resistant
Major Depressive Disorder
Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Depression
The purpose of the study is to determine the efficacy, safety and pharmacokinetics of inhaled Esketamine in participants with treatment-resistant depression (TRD) in the course of Major Depressive Disorder (MDD).
- Trial name
- NCT03965858
- Testing
- Esketamine DPI - low dose, Esketamine DPI - medium dose, Esketamine DPI - high dose
- Where
- 12 sites in Poland
- Volunteers
- 88 people
- Sponsor
- Celon Pharma SA
Resistant Depression, Moods Disorders
tDCS as an add-on Treatment for Resistant Major Depression in Uni- or Bipolar Patients
The aim is to investigate the effect of transcranial Direct Current Stimulation (tDCS) applied at the anodal left CDLPF of patients with resistant depression compared to patients treated with conventional therapy.
- Conditions
- Resistant Depression, Moods Disorders, Unipolar Depression, Bipolar Disorder
- Trial name
- STICODEP (NCT01644747)
- Testing
- transcranial Direct Current Stimulation (tDCS) (Eldith DC NeuroConn Stimulator)
- Where
- 6 sites in France
- Volunteers
- 87 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Treatment Resistant Depression
TBS in Major Depression
Background Major depression is associated with morbidity and increased mortality. Along with the psychological strain depression represents a high socioeconomic burden costing Europe more than €113 billion/year.
- Trial name
- NCT03257397
- Testing
- theta-burst stimulation (TBS) using a MagPro X1000
- Where
- Austria
- Volunteers
- 80 people
- Sponsor
- Rupert Lanzenberger
ASD, Autism Spectrum Disorder
Theta Burst Stimulation for Refractory Depression in Autism Spectrum Disorder
Evaluate the efficacy of accelerated theta burst stimulation (aTBS) in reducing depressive symptoms in autism spectrum disorder (ASD)
- Conditions
- ASD, Autism Spectrum Disorder, Autism, Depression - Major Depressive Disorder
- Trial name
- RETSORE-RCT (NCT06670040)
- Testing
- Transcranial Magnetic Stimulation
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Bipolar Disorder
The Treatment of Children and Adolescents With Treatment-Resistant Depression
This study seeks to learn about brain function in adolescents with depression and to determine whether adding lithium carbonate to antidepressant medication can reduce depression in children and adolescents.
- Trial name
- NCT00029640
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- National Institute of Mental Health (NIMH)
Depression; Bipolar Disorder
Comparing Different Patterns of rTMS in Major Depression
This trial will compare the trajectories of improvement for three different patterns of twice-daily rTMS in major depression: two daily sessions of dorsomedial prefrontal rTMS delivered at 0 min vs. 30 min vs. 60 min intervals.
- Trial name
- NCT02778035
- Testing
- Dorsomedial prefrontal rTMS
- Where
- 2 sites in Canada
- Volunteers
- 180 people
- Sponsor
- University Health Network, Toronto
Treatment Resistant Depression
Rapid Acting Transcranial Magnetic Stimulation
This study evaluates an accelerated schedule of theta-burst stimulation using a transcranial magnetic stimulation device for treatment-resistant depression.
- Trial name
- NCT04739969
- Testing
- Active TBS-DLPFC
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Stanford University
Depressive Disorder, Treatment-Resistant
Personalized rTMS for Resistant Depression
The investigators hypothesize that personalizing the rTMS targets using functional MRI will increase its efficacy. The most dysfunctional regions or the most dysfunctional network will be stimulated homogeneously.
- Trial name
- NCT02863380
- Testing
- Functional magnetic resonance imaging used to individualize rTMS protocol, Individualized rTMS (transcranial magnetic stimulation), Classical rTMS (transcranial magnetic stimulation)
- Where
- France
- Volunteers
- 27 people
- Sponsor
- University Hospital, Strasbourg, France
Bipolar Disorder (BD), Suicidality
Neural Correlates of Ketamine's Anti-suicidal Effects in Bipolar Depression
Bipolar disorder is characterized by manic episodes and episodes of extreme depressive feelings, also known as bipolar depression (BD).
- Trial name
- DEEPP (NCT05177146)
- Testing
- Intravenous Ketamine (IV)
- Where
- Canada
- Volunteers
- 16 people
- Sponsor
- Centre for Addiction and Mental Health
Bipolar Disorder, Bipolar Depression
Ketamine for Treatment-Resistant Bipolar Disorder
Growing evidence has supported rapid and robust antidepressant effects with subanesthetic doses of intravenous (IV) ketamine for treatment resistant depression (TRD).
- Conditions
- Bipolar Disorder, Bipolar Depression, Bipolar I Disorder, Bipolar II Disorder
- Trial name
- KET-BD (NCT05004896)
- Testing
- Ketamine Hydrochloride, Midazolam Hydrochloride
- Where
- 3 sites in Canada
- Volunteers
- 71 people
- Sponsor
- Joshua Rosenblat
Treatment-resistant Depression (TRD)
Personalized DBS Targeting for Treating Depression
The goal of this clinical trial is to optimize the target brain areas for deep brain stimulation (DBS) for depression based on personalized brain imaging and stereo-electroencephalography（SEEG), to administer long-term DBS…
- Trial name
- NCT06784388
- Testing
- Deep Brain Stimulation(DBS), Esketamine
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Depressive Disorder, Treatment-Resistant
A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression
The purpose of this study is to evaluate the efficacy and safety of switching elderly participants with treatment-resistant depression (TRD) from a prior antidepressant treatment (to which they have not responded) to either…
- Trial name
- TRANSFORM-3 (NCT02422186)
- Testing
- Esketamine, Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant)
- Where
- 69 sites in United States, Belgium and 10 more
- Volunteers
- 139 people
- Sponsor
- Janssen Research & Development, LLC
Treatment Resistant Depression
Tianeptine for Treatment Resistant Depression
The studies will be conducted in parallel at two sites: the the Mood and Anxiety Disorders Program at the Icahn School of Medicine at Mount Sinai (MSSM), and Stanford Depression Research Clinic at Stanford University School of…
- Trial name
- NCT04249596
- Testing
- Tianeptine Sodium
- Where
- 3 sites in United States
- Volunteers
- 38 people
- Sponsor
- Jonathan A. Javitch, MD, PhD
Depression, Major Depressive Disorder
pBFS-guided High-dose TMS Over DMPFC for Treatment-resistant Major Depressive Disorder
The investigators aim to evaluate the safety and efficacy of pBFS-guided DMPFC target and high-dose rTMS therapy for the treatment of patients with treatment-resistant depression
- Conditions
- Depression, Major Depressive Disorder, Severe Depression
- Trial name
- NCT05964036
- Testing
- active TMS
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Changping Laboratory
Depressive Disorder, Treatment-Resistant
Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant Depression
This study evaluated the efficacy and safety of the compound MIJ821 compared to placebo in patients aged from 18 to 65 years diagnosed with treatment-resistant depression. The study was conducted in the US and in Europe (Spain).
- Trial name
- NCT03756129
- Testing
- MIJ821, Ketamine
- Where
- 12 sites in United States, Spain
- Volunteers
- 70 people
- Sponsor
- Novartis Pharmaceuticals
Depression
Aripiprazole as Augmentation for TRD
A sizeable minority of patients suffering from major depression do not have their full set of depressive symptoms relieved by a single medication.
- Trial name
- NCT00174876
- Testing
- Drug Abilify
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- State University of New York - Upstate Medical University
Treatment Resistant Depression
KET-RO Plus RO DBT for Treatment Resistant Depression
This pilot study will assess the safety and feasibility of intravenous (IV) ketamine combined with RO DBT in young adults with Treatment-Resistant Depression (TRD).
- Trial name
- KET-RO (NCT06138691)
- Testing
- Ketamine Infusion plus RO DBT
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Washington University School of Medicine
Treatment Resistant Depression (TRD)
Study of rTMS in Maintenance in Treatment Resistant Depression
The goal of this clinical trial is to learn which treatment works better to help people with treatment-resistant depression stay well after they improve with repetitive transcranial magnetic stimulation (rTMS), a non-invasive…
- Trial name
- NCT07760168
- Testing
- Transcranial Magnetic Stimulation, quetiapine
- Volunteers
- 68 people
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
Treatment Resistant Depression
A Study in Relapse Prevention of Treatment-Resistant Depression
The purpose of this study is to determine whether olanzapine and fluoxetine combination (OFC) if used for a long time (47 weeks) makes patients suffering from Treatment Resistant Depression stable, determine if OFC is safe when…
- Trial name
- NCT00958568
- Testing
- Olanzapine and Fluoxetine combination (OFC), Fluoxetine
- Where
- 66 sites in United States, Argentina and 6 more
- Volunteers
- 892 people
- Sponsor
- Eli Lilly and Company
Treatment Resistant Depression
Brain-derived Neurotrophic Factor and the Antidepressant Efficacy of Brain Stimulation
This study evaluates an association between brain-derived neurotrophic factor(BDNF) polymorphisms and the antidepressant efficacy of transcranial magnetic stimulation device in patients with treatment-resistant depression.
- Trial name
- NCT04076124
- Testing
- Active rTMS-DLPFC, Active iTBS-DLPFC
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan